# The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

> **NCT02395640** · PHASE3 · COMPLETED · sponsor: **Fudan University** · enrollment: 438 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02395640
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2021-02-23
- **Final completion:** 2021-02-23
- **Target enrollment:** 438 (ESTIMATED)
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02395640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02395640, "The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02395640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*